Glucagon-like peptide-1 (GLP-1) receptor agonists

Adding a weekly semaglutide injection in people already using basal insulin to treat type 2 diabetes avoids the need for prandial insulin, show the SUSTAIN 11 findings.

People who lose weight while taking semaglutide 2.4 mg regain two-thirds of what they lost during the first year after stopping the medication, shows the STEP 1 extension study.

Real-world data confirm glycated hemoglobin and weight benefits, albeit attenuated, for people with type 2 diabetes switching to injectable semaglutide from other GLP-1 receptor agonists.

Click through to read more on this announcement

Only a third of people given a glucagon-like peptide-1 receptor agonist in clinical practice lose a clinically meaningful amount of weight, potentially due to high rates of discontinuation, say researchers.

The STEP 6 findings reveal significant weight loss, along with a reduction in abdominal visceral fat, in east Asian people with obesity taking a high dose of semaglutide.

Data from primary care suggest that use of sodium-glucose cotransporter2 inhibitors, and possibly glucagon-like peptide-1 receptor agonists, may reduce the risk for cardiovascular disease events in people with type 2 diabetes without previous events.

Semaglutide 2.4 mg produces substantially more weight loss than liraglutide 3.0 mg in people with overweight or obesity but without diabetes, say the STEP 8 investigators.

A phase 3 cardiovascular safety trial finds exenatide delivered from an osmotic mini-pump to be noninferior to placebo.

The cardiovascular benefits of the GLP-1 receptor agonist efpeglenatide are unrelated to concurrent SGLT2 inhibitor use, suggests an exploratory analysis of AMPLITUDE-O trial data.

Click through to read more on this announcement

Reducing the cost of SGLT2 inhibitors by around 17% would make them cost-effective for use in people with type 2 diabetes in low- and middle-income countries, study findings indicate.

The addition of liraglutide rather than extra oral antidiabetic drugs may offer more sustained glycemic control for people with type 2 diabetes who have inadequate control with metformin, suggest findings of the international LIRA-PRIME study.

A real-world study shows a reduced risk for heart failure hospitalization, even in people without pre-existing cardiovascular disease, with use of SGLT2 inhibitors versus GLP-1 receptor agonists.

Semaglutide treatment results in significant reductions in levels of the inflammatory marker high-sensitivity C-reactive protein, indicates further analysis of the PIONEER and SUSTAIN trials.

Findings from a phase 3 randomized crossover trial suggest that 7 weeks of treatment with liraglutide may improve forced vital capacity among people with type 2 diabetes and impaired lung function.

Treatment with the GLP-1 receptor agonist liraglutide is associated with a reduction in cardiac adipose tissue volume among people with type 2 diabetes, suggests a secondary analysis of data from the LiraFlame trial.

The 10-year and lifetime CVD risk of people with type 2 diabetes varies greatly, with the highest risk seen in those with prior CVD, suggests an analysis of data from the CAPTURE study.

A post-hoc analysis of SUSTAIN 10 indicates that people with type 2 diabetes stand to gain from GLP-1 receptor agonist use even if they are already using an SGLT2 inhibitor.

The real-world STAY study suggests that people take GLP-1 receptor agonists more consistently and for longer if given a weekly rather than daily formulation.